- Patient/Guest
- Phlebotomist
- Updates
| Ovarian Panel | - |
|---|
|
Measure ovarian cancer markers |
||
 |
Synonym | See updates |
 |
Test Code | CDBIOPR0039 |
 |
Test Type | Biochemistry |
 |
Pre-Test Condition | See updates |
 |
Report Availability | 2 D(s) |
 |
# Test(s) | Multiple |
| Test details | Sample Report |
|---|---|
| Ovarian Panel |
|
|
Synonym | See updates | |
|
Test Code | CDBIOPR0039 | |
 |
Test Category | Ovarian cancer | |
|
Pre-Test Condition | See updates | |
 |
Medical History | See updates | |
|
Report Availability | 2 D(s) | |
 |
Specimen/Sample | Serum; 2 mL; SST | |
 |
Stability @21-26 deg. C | 6 Hr(s) | |
 |
Stability @ 2-8 deg. C | 7 D(s) | |
 |
Stability @ Frozen | 1 M(s) | |
|
# Test(s) | Multiple | |
 |
Processing Method | Chemiluminescence | |
| **Ovarian Cancer Panel****FDA Status**: FDA-approved for ovarian cancer diagnostics.**Other Names**: Ovarian Tumor Marker Panel, CA-125/HE4 Test.**Historical Breakthrough**: Developed in the 1990s for ovarian cancer monitoring, advancing oncology.**Key Purpose and Impact**: Tests CA-125, HE4, and other markers to diagnose or monitor ovarian cancer.**Preparation and Patient History**: Blood; report pelvic mass, bloating, or cancer history.**Consent Requirement**: Standard consent for diagnostic testing.**Clinical Value**: Sensitivity ~90%; specificity ~95%; detects ovarian cancer in ~70% of cases; guides therapy.**References Cited**: Testing.com Oncology Tests 2023; Labcorp Ovarian Panel 2025; UpToDate Ovarian Cancer 2025 |